GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has published its audited financial results for the quarter and year ended 31 March 2025 in Economic Times, Business Standard, and Maharashtra Times, as required under SEBI listing rules. On a standalone basis, full-year revenue from continuing operations grew to ₹3,72,349 lakhs from ₹3,40,725 lakhs in FY24, a rise of about 9%. Net profit after tax for the year jumped to ₹91,906 lakhs from ₹58,469 lakhs, helped by the absence of a large one-time exceptional charge that had hit the previous year. For Q4FY25 alone, standalone net profit rose to ₹26,014 lakhs from ₹19,308 lakhs, with revenue of ₹96,608 lakhs vs ₹91,087 lakhs in Q4FY24. Consolidated FY25 net profit came in at ₹92,758 lakhs vs ₹58,996 lakhs in FY24. The Board has recommended a final dividend of ₹42 per share, up from ₹32 per share last year.
Shareholders get a healthy ~31% hike in final dividend alongside strong profit growth, signaling solid year-end performance; this is likely to be viewed positively by the market.